Pharmacology Journal of Pharmacology and Experimental Therapeutics (ASPET)
Bcl-xL inhibition curbs retinal fibrosis in a cell coculture model
- A self-assembling retinal coculture modeled fibrosis; standard anti-VEGF agents showed no measurable antifibrotic effect.
- A pilot screen flagged Bcl-xL as a promising target, and the clinical candidate inhibitor UBX-1325 was tested against it.
- UBX-1325 induced apoptosis in activated Müller cells and suppressed fibrotic activation in RPE cells without apoptosis.
- BCL2L1 expression was higher in patient proliferative vitreoretinopathy membranes than in epiretinal membranes.
Anti-VEGF failing is a low bar to clear, so that comparator says little about Bcl-xL. On-target proof comes first: Bcl-xL knockdown or an inactive analog in the same coculture, because Bcl-2 family inhibitors can overlap in selectivity. After that, an intravitreal PVR animal model with measured retinal exposure, since a dish has no vitreous or clearance.
Paper: Journal of Pharmacology and Experimental Therapeutics (ASPET) ↗ A self-assembling coculture model of retinal fibrosis reveals Bcl-xL inhibitors as cell-selective dual-mechanism antifibrotics